OMH Osmetech

Osmetech plc (LSE:OMH), the international molecular diagnostics company, announces that its exclusive CYP450 4F2 biomarker has been included on the leading warfarin dosing website, www.warfarindosing.org, a free Web site to aid doctors and other clinicians in warfarin therapy by estimating the therapeutic dose in patients new to warfarin or within first 4 INRs.

James White, Chief Executive Officer, Osmetech plc, said:

"The inclusion of 4F2, exclusively licensed to Osmetech, is further recognition of the importance of the biomarker�s role in establishing a safe and appropriate personalized dose for each patient.

"The high performance of our eSensor XT-8 System and Warfarin Sensitivity Test in the market combined with our unique 4F2 biomarker gives us �best platform� and �best test.� This combination further positions Osmetech as the leader in this market, which we believe is poised for significant growth.�

Warfarin sensitivity testing

Warfarin is an oral anticoagulant widely used for the prevention of thrombotic events and to treat a confirmed episode of venous thrombosis, with approximately 2 million new patients each year in the US alone. Although highly effective, warfarin�s usability is limited by a narrow therapeutic range combined with a pronounced interindividual variability in the dose required for adequate anticoagulation. Clinical use of warfarin is further complicated by a substantial risk for hemorrhagic side effects, which is increased in patients with low-dose requirements. Warfarin is the second-most-likely drug, after Digoxin, to cause adverse events requiring hospitalization.

Osmetech (LSE:OMH)
Historical Stock Chart
From Jan 2025 to Feb 2025

Osmetech (LSE:OMH)
Historical Stock Chart
From Feb 2024 to Feb 2025